menu
    • menu
    [{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Emricasan","moa":"Caspase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Meridian Bioscience \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Emricasan","moa":"Caspase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Meridian Bioscience \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Radiolabeled Compound","year":"2011","type":"Inapplicable","leadProduct":"13-C Sodium Octanoate","moa":"Fatty acid metabolism","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Meridian Bioscience \/ Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization","highestDevelopmentStatusID":"8","companyTruncated":"Meridian Bioscience \/ Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"BMS-986036","moa":"FGF1\/KLB","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Meridian Bioscience \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Meridian Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Caprylic Acid","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Meridian Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Meridian Bioscience \/ Meridian Bioscience"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Benzoyl-L-Tyrosyl-Alanine","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Meridian Bioscience \/ Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India","highestDevelopmentStatusID":"8","companyTruncated":"Meridian Bioscience \/ Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Breathid Hp Lab System","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Meridian Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Meridian Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Grapefruit Juice","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Meridian Bioscience","highestDevelopmentStatusID":"9","companyTruncated":"Meridian Bioscience \/ Meridian Bioscience"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Ethan Weinberg","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Ethan Weinberg","highestDevelopmentStatusID":"8","companyTruncated":"Meridian Bioscience \/ Ethan Weinberg"}]

    Find Clinical Drug Pipeline Developments & Deals by Meridian Bioscience

    Menu

    Meridian Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986036

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

                            Details : BMS-986036 is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 02, 2018

                            Lead Product(s) : BMS-986036

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ursodeoxycholic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Ethan Weinberg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

                            Details : Ursodeoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoidosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 27, 2018

                            Lead Product(s) : Ursodeoxycholic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ethan Weinberg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emricasan

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Conatus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

                            Details : Emricasan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Cirrhosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2018

                            Lead Product(s) : Emricasan

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Conatus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emricasan

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Conatus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

                            Details : Emricasan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2018

                            Lead Product(s) : Emricasan

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Conatus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Breathid Hp Lab System

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics

                            Details : Breathid Hp Lab System is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helicobacter Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 19, 2016

                            Lead Product(s) : Breathid Hp Lab System

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 13-C Sodium Octanoate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

                            Details : 13-C Sodium Octanoate is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Diseases.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 13, 2011

                            Lead Product(s) : 13-C Sodium Octanoate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzoyl-L-Tyrosyl-Alanine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency

                            Details : Benzoyl-L-Tyrosyl-Alanine is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatitis, Chronic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 14, 2010

                            Lead Product(s) : Benzoyl-L-Tyrosyl-Alanine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Caprylic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

                            Details : Sodium Octanoate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Metabolic Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 19, 2010

                            Lead Product(s) : Caprylic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Meridian Bioscience

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grapefruit Juice

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II/ Phase III

                            Recipient : Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ¹³C-Methacetin Breath Test (MBT) Methodology Study

                            Details : Grapefruit Juice is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Liver Diseases.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 20, 2010

                            Lead Product(s) : Grapefruit Juice

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth